Do you want BuboFlash to help you learning these things? Or do you want to add or correct something? Click here to log in or create user.



Question
The three anti-TNF agents approved for CD are infliximab, adalimumab, and certolizumab. Because [...] is pegylated, it should have very little, if any, placental transfer and therefore is favored by some clinicians in a pregnant patient over the other two agents.
Answer
certolizumab

Question
The three anti-TNF agents approved for CD are infliximab, adalimumab, and certolizumab. Because [...] is pegylated, it should have very little, if any, placental transfer and therefore is favored by some clinicians in a pregnant patient over the other two agents.
Answer
?

Question
The three anti-TNF agents approved for CD are infliximab, adalimumab, and certolizumab. Because [...] is pegylated, it should have very little, if any, placental transfer and therefore is favored by some clinicians in a pregnant patient over the other two agents.
Answer
certolizumab
If you want to change selection, open original toplevel document below and click on "Move attachment"

Parent (intermediate) annotation

Open it
The three anti-TNF agents approved for CD are infliximab, adalimumab, and certolizumab. Because certolizumab is pegylated, it should have very little, if any, placental transfer and therefore is favored by some clinicians in a pregnant patient over the other two agents.

Original toplevel document (pdf)

owner: ELBOMBARDO - (no access) - MKSAP_17.pdf, p2619

Summary

statusnot learnedmeasured difficulty37% [default]last interval [days]               
repetition number in this series0memorised on               scheduled repetition               
scheduled repetition interval               last repetition or drill

Details

No repetitions


Discussion

Do you want to join discussion? Click here to log in or create user.